AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Gastrin/cholecystokinin type B receptor

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P32239

UPID:

GASR_HUMAN

Alternative names:

Cholecystokinin-2 receptor

Alternative UPACC:

P32239; A8K7P9; O75824; Q16144; Q92492; Q96LC6; Q9NYK7; Q9UBV1

Background:

The Gastrin/cholecystokinin type B receptor, also known as the Cholecystokinin-2 receptor, plays a pivotal role in various physiological processes. It functions as a receptor for gastrin and cholecystokinin, influencing anxiety, analgesia, arousal, and neuroleptic activity in the central nervous system. Additionally, it activates a phosphatidylinositol-calcium second messenger system through G proteins.

Therapeutic significance:

Understanding the role of the Gastrin/cholecystokinin type B receptor could open doors to potential therapeutic strategies. Its involvement in modulating key neurological functions and possibly regulating cancer cell proliferation via a gastrin-independent mechanism highlights its significance in therapeutic applications.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.